Strikingly, the ErbB2 protein is overexpressed in over 50% of early stage non-invasive breast cancers (ductal carcinoma in situ, DCIS) [13]; yet, it is overexpressed in only approximately 25% of later stage invasive and metastatic breast cancers [7]. Here, ERBB2 is linked to ductal breast carcinoma in situ.